AlphAIAlphAI — Financial news for AI agents
BenzingaOCT 312 min read$ITRI

This Itron Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Comcast (NASDAQ:CMCSA), Bicycle Therapeutics (NASDAQ:BCYC)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Original reporting
Benzinga · Avi Kapoor
Published Oct 31, 2025, 12:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 31, 2025, 1:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$ITRI
Neutral
medium confidence
Mentioned
$ITRI · $CCZ · $BCYC
Relevance
6/10
AlphAI data visualization · based on Benzinga
Decision brief

The 30-second read

$ITRINeutralMed
01

Why it matters

While downgrades can lead to short-term declines, the mixed sentiment and technical support levels suggest limited downside for some stocks.

02

Market read

The news has moderate relevance for traders focusing on the impacted sectors, with limited broader market implications.

03

What to watch

Broader market conditions and upcoming earnings reports could influence stock movements independently of analyst ratings.

Relevance 6/10Timing: Immediate to short-term

Background

Recent analyst downgrades on key stocks in Life Sciences and Technology sectors have caused some concern among traders.

Company-level read

Ticker impact

$ITRINeutralMedium confidence
Context

High relevance due to recent analyst downgrade and somewhat bullish sentiment.

Expected impact

Moderate short-term decline followed by stabilization.

Evidence & confidence

The downgrade indicates caution, but the mixed sentiment and lack of technical breakdowns suggest limited downside.

$CCZNeutralLow confidence
Context

Low relevance; neutral sentiment and no recent analyst activity.

Expected impact

Likely negligible price movement.

Evidence & confidence

Relevance score is low; no significant analyst activity or sentiment change.

$BCYCBullishMedium confidence
Context

Moderate relevance; somewhat bullish sentiment but recent analyst downgrade.

Expected impact

Possible short-term increase, then consolidation.

Evidence & confidence

Mixed signals imply cautious optimism; technical support levels may hold.

Market effects

Sector

Potential sector-wide caution in Life Sciences and Technology sectors due to analyst downgrades.

Regional

Limited regional impact; news pertains mainly to US-listed companies.

Global

Low; specific to individual companies with limited global influence.

Counterpoint

What could challenge this read

The analyst downgrade may be overreacting; fundamentals could support the stocks, leading to a quick recovery.

Key entities

  • Author
    Avi Kapoor

    Financial analyst and writer at Benzinga.

  • Source
    Benzinga

    Financial news and analysis platform.

Read at source← All news

Related articles

OCT 29
$BCYCMed

Bicycle Therapeutics plc: Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results

Bicycle Therapeutics (BCYC) reported Q3 2026 financial results and business updates. Nuzefatide pevedotin received FDA Orphan Drug Designation for pancreatic cancer treatment. The company has $469.9M in cash, expecting runway into 2030. Clinical trials for nuzefatide and BT1702 are ongoing, with updates expected in 2027. Collaboration revenue increased to $34.1M, while R&D and G&A expenses decreased.

finanznachrichten.de6 min
OCT 29
$BCYCMed

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results

BICYCLE THERAPEUTICS PLC (BCYC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results Nuzefatide pevedotin granted FDA Orphan Drug Designation for the treatment of pancreatic cancer; further updates expected in 2027 Initiation of the first company-sponsored

SEC EDGAR 8-K2 min
OCT 29
$BCYCMedAI 8/10

Bicycle Therapeutics reports Q3 results, FDA orphan status

Bicycle Therapeutics (BCYC) reported Q3 2026 results, with cash of $469.9M and collaboration revenue of $34.1M. The FDA granted Orphan Drug Designation to nuzefatide pevedotin for pancreatic cancer. The company expects its cash runway to extend into 2030 and plans to initiate a radioligand clinical trial for BT1702 in 2H 2027. Net loss was $10.5M, or $0.15 per share, compared to $59.1M, or $0.85 per share, in Q3 2025.

investing.com2 min
OCT 28
$ITRIMed

Oppenheimer reiterates Itron stock rating on earnings beat

Oppenheimer maintained an Outperform rating and $135 price target for Itron (ITRI) after its Q3 earnings beat. The stock trades at $94.55 with a $4.15B market cap. Itron reported non-GAAP EPS of $1.94, above estimates, and revenue of $599.3M. Analysts expect mid-single-digit topline growth by FY2027, with a consensus Buy rating and targets ranging from $105 to $150.

investing.com1 min
OCT 28
$ITRIMed

Needham maintains Buy rating on Itron, $137 price target

Needham kept its Buy rating on Itron (ITRI) with a $137 price target, suggesting a 44.9% upside from the Oct 27 close. The firm cited Itron's strong 3Q2026 results, including adjusted EPS of $1.94, and a 25% year-over-year increase in annual recurring revenue, according to the analyst note.

tradingview.com1 min